These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1407246)

  • 1. Parkinson's disease in Taiwan: an analysis of 215 patients.
    Chia LG; Liu LH
    Neuroepidemiology; 1992; 11(3):113-20. PubMed ID: 1407246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations.
    Sato K; Hatano T; Yamashiro K; Kagohashi M; Nishioka K; Izawa N; Mochizuki H; Hattori N; Mori H; Mizuno Y;
    Mov Disord; 2006 Sep; 21(9):1384-95. PubMed ID: 16763980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Progress in the basic and clinical aspects of Parkinson's disease].
    Mizuno Y
    Rinsho Shinkeigaku; 2004 Nov; 44(11):741-50. PubMed ID: 15651281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of early dopa treatment in Parkinson's disease.
    Markham CH; Diamond SG
    Ann Neurol; 1986 Apr; 19(4):365-72. PubMed ID: 3707088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course of patients with idiopathic Parkinson's disease.
    Roos RA; Jongen JC; van der Velde EA
    Mov Disord; 1996 May; 11(3):236-42. PubMed ID: 8723138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinsonism treated with levodopa: progression and mortality.
    Maier Hoehn MM
    J Neural Transm Suppl; 1983; 19():253-64. PubMed ID: 6583311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
    Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
    West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease.
    Scigliano G; Musicco M; Soliveri P; Piccolo I; Girotti F; Giovannini P; Caraceni T
    Neurology; 1990 Feb; 40(2):265-9. PubMed ID: 2300246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.
    Uitti RJ; Ahlskog JE; Maraganore DM; Muenter MD; Atkinson EJ; Cha RH; O'Brien PC
    Neurology; 1993 Oct; 43(10):1918-26. PubMed ID: 8413948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
    Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
    J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of antiparkinsonism drugs in 92 cases in Xi'an city].
    Zhe X; Qu QM; Wang RL; Cao HM; Qiao J; Guo F
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Oct; 30(10):1065-8. PubMed ID: 20193391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parkinson's disease: progression and mortality.
    Hoehn MM
    Adv Neurol; 1987; 45():457-61. PubMed ID: 3825726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Motor levodopa-induced complications in Parkinson's disease].
    Michałowska M; Fiszer U; Szatanowski T
    Pol Merkur Lekarski; 2016 Jun; 40(240):357-61. PubMed ID: 27403901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
    Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
    J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson's disease with severe motor fluctuations: a 2-year follow-up review.
    Ghika J; Villemure JG; Fankhauser H; Favre J; Assal G; Ghika-Schmid F
    J Neurosurg; 1998 Nov; 89(5):713-8. PubMed ID: 9817406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of treatment with levodopa on Parkinson's disease.
    Shaw KM; Lees AJ; Stern GM
    Q J Med; 1980; 49(195):283-93. PubMed ID: 7465763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.